|
Gelatinase-A (MMP-2)
|
No
|
• None [56]
|
• Reduction in angiogenesis and tumor growth [57]
|
|
Stromelysin-1 (MMP-3)
|
No
|
• None [58]
|
• Impaired wound contraction [59]
|
| | | |
• Reduced contact hypersensitivity response [60]
|
| | | |
• Accelerated arthritis [58]
|
|
Matrilysin (MMP-7)
|
No
|
• Lack of activated antimicrobial peptides [19]
| ✓ Inability to repair mucosal epithelial wounds [39]
|
| | | |
• Reduced ability to kill pathogenic bacteria [19]
|
| | | |
• Reduced tumorigenesis [61]
|
|
Gelatinase-B (MMP-9)
|
No
|
• Transient slowing of long bone growth
| ✓ Normal neutrophil extravasation [63]
|
| | |
secondary to reduced angiogenesis [62]
| ✓ Lack of alveolar brochiolization in fibrosis [45]
|
| | | |
• Resistant to induced blister formation [22,64]
|
| | | |
• Persistent contact hypersensitivity response [60]
|
| | | |
• Protection against aortic aneurysm formation [65]
|
| | | |
• Reduced ventricular enlargement and rupture
|
| | | |
postmyocardial infarction [66,67]
|
| | | |
• Delayed tumor progression and reduced metastases [68]
|
|
Stromelysin-3 (MMP-11)
|
No
|
• None [69]
|
• Less chemically induced tumors and reduced tumor
|
| | | |
cell implantation [69]
|
| | | |
• Accelerated and enhanced neointimal formation [70]
|
|
Macrophage
|
No
|
• None [53]
| ✓ Reduced elastolytic capacity of macrophages [53]
|
|
metalloelastase (MMP-12)
| | | ✓ Protection against smoking-induced |
| | | |
emphysema [54]
|
| | | |
• Reduced ability of macrophages to migrate through
|
| | | |
matrix [53]
|
|
MT1-MMP (MMP-14)
|
Yes
|
• Severe skeletal abnormalities [71]
|
• Not yet assessed
|
